Sun-037 no impact of newly initiated immunosuppressive therapy observed on long-term antiproteinuric effect of sparsentan in focal segmental glomerulosclerosis: interim 84-week analysis of the duet trial

Sparsentan, a first-in-class, orally active, dual-acting, selective antagonist of the angiotensin II type 1 receptor and the endothelin type A receptor, is in development for the treatment of focal segmental glomerulosclerosis (FSGS). In the ongoing DUET trial in patients with FSGS, sparsentan 200, 400, and 800 mg/d resulted in greater reduction in proteinuria versus irbesartan 300 mg/d over an 8-week double-blind period. Sparsentan continues to be evaluated in an open-label extension (OLE) of the DUET trial.